Top Markets
#1 Islamic Coin Islamic Coin +154.32%
#2 PulseChain PulseChain +51.99%
#3 BOOK OF MEME BOOK OF MEME +44.46%
#4 DogBull DogBull +35.05%
#5 ORDI ORDI +19.01%
#6 Nockchain Nockchain +17.37%
#7 rsERG rsERG +17.11%
#8 Ergo Ergo +16.94%
#9 PondCoin PondCoin +16.09%
#10 Victoria VR Victoria VR +16.01%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Classement en actions #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Prix de l'action
$1.48
Dernière synchronisation: 2023-05-31
Capitalisation boursière
$35.54M
Changement (1 jour)
-5.73%
Changement (1 an)
0.00%
Pays
US
Échange TCR2 Therapeutics Inc. (TCRR)

Catégorie

Healthcare
Ratio P/B pour TCR2 Therapeutics Inc. (TCRR)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de TCR2 Therapeutics Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour TCR2 Therapeutics Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH